Mr. Fare has nearly 40 years’ experience in drug discovery research, in drug development, and in business development. From 2016 to 2023, Mr. Fare served as Chief Operating Officer of two companies, backed by private equity, Skinject, Inc., a company developing tip-loaded, dissolvable microneedle arrays for therapeutic applications, and Dermal Biomics, Inc., a company developing consumer healthcare products for diabetic women. Mr. Fare was a founding member of The Institutes for Pharmaceutical Discovery, L.L.C. (IPD), a diversified biopharmaceutical company. As Chief Operating Officer at IPD from 1995 to 2013, Mr. Fare had executive responsibility for several facets of the company’s business: drug discovery research, business development, client management, project management, finance/accounting, facilities management, and information technology. He was responsible for the performance of the Institute for Bioanalytics, L.L.C., which developed customized immunoassays for bioanalytical purposes; the Institute for Drug Discovery, which collaborated with elite universities to transform early-stage targets into drug discovery programs; and the Institute for Diabetes Discovery, L.L.C., which focused on the discovery and development of novel therapeutics for metabolic disease. Prior to his responsibilities at IPD, Mr. Fare was a Director of Strategic Planning and New Product Marketing for Wyeth-Ayerst International, a subsidiary of American Home Products Company. Mr. Fare holds a Bachelor of Arts from St. Joseph’s University and Master of Science degree from Drexel University.